710 Medtronic Parkway, NE
Medtronic, headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world.
Founders: Earl Bakken and Palmer Hermundlie
CEO: Omar Ishrak
CFO: Karen Parkhill
CSO (Scientific): Richard Kuntz
Please click here for Medtronic job opportunities.
Tweets by Medtronic
2119 articles with Medtronic
New EndoSuture Aneurysm Repair (ESAR) and Valiant Navion(TM) Data Presented at Charing Cross Demonstrate Safety and Efficacy in Patients with Complex Anatomies
Medtronic VenaSeal(TM) Closure System Demonstrates Durable and Consistent Outcomes at Five Years in Patients with Chronic Venous Disease
Medtronic plc announced five-year outcomes from the VeClose Extension Study.
Positive HVAD LATERALTM Study Results Also Now Published in The Journal of Heart and Lung Transplantation
Medtronic HeartWare(TM) HVAD(TM) System Demonstrates Reduction in Total Strokes, Disabling Strokes and Stroke-Related Mortality with Blood Pressure Management
Company Has Initiated a Post-Approval Study of Heart Failure Management Best Practices to Further Demonstrate Improved Patient Outcomes
Early-Stage Business Accelerator to Empower Local MedTech Innovation and Enhance Medtronic China's Industry Leadership
New Clinical Trial Shows Medtronic TYRX(TM) Envelope Signficantly Reduces Major Infections in Cardiac Implantable Device Patients
WRAP-IT is the Largest Randomized Global Trial Ever Conducted with Cardiac Implanted Electronic Devices
Less Invasive Evolut(TM) Transcatheter Aortic Valve Replacement (TAVR) System Successful in Clinical Trial When Compared to Open Heart Surgery in Healthier Aortic Stenosis Patients
As the American College of Cardiology (ACC) annual meeting opens in New Orleans this weekend, one of the big stories will undoubtedly be on the role of wrist sensors, such as the Apple Watch, in identifying heart rhythm problems. There will be other big stories, of course. Here’s a preview of jus...
DUBLIN - March 14, 2019 - Medtronic plc announced that its Board of Directors has appointed Andrea J. Goldsmith, Ph.D. to the Board as an independent director, effective March 11, 2019.
VIVA Physicians Selects NAMSA as Statistical Analytic Group to Evaluate the Safety of Paclitaxel Drug-Eluting Technologies in PAD
VIVA Physicians announced the selection of NAMSA as the independent statistical analysis group to examine individual patient-level data associated with paclitaxel-coated balloons and stent trials used in the treatment of peripheral artery disease in the superficial femoral artery.
Board Authorizes $6 Billion for Share Repurchases
Medtronic Announces Closing of Public Offering of Senior Notes; Acceptance of Tendered Notes; and Redemption of Certain Senior Notes
Medtronic Global Holdings S.C.A. has closed a registered public offering of €500,000,000 principal amount of Floating Rate Senior Notes due 2021, €1,500,000,000 principal amount of 0.000% Senior Notes due 2021, €1,500,000,000 principal amount of 0.375% Senior Notes due 2023, €1,500,000,000 principal amount of 1.125% Senior Notes due 2027, €1,000,000,000 principal amount of 1.625% Senior Notes due 2031 and €1,000,000,000 principal amount of 2.250% Senior Notes due 2039.
Medtronic Global Holdings S.C.A., has priced an offering of €500,000,000 principal amount of floating rate senior notes due 2021, €1,500,000,000 principal amount of 0% senior notes due 2021, €1,500,000,000 principal amount of 0.375% senior notes due 2023, €1,500,000,000 principal amount of 1.125% senior notes due 2027, €1,000,000,000 principal amount of 1.625% senior notes due 2031, and €1,000,000,000 principal amount of 2.250% senior notes due 2039.
Medtronic Announces the Upsizing of its Maximum Tender Offers for Certain Outstanding Debt Securities Issued by Medtronic, Inc. and Covidien International Finance S.A.
Medtronic plc announced the upsizing of the previously-announced cash tender offers by its wholly-owned subsidiaries, Medtronic, Inc.
Medtronic plc, the global leader in medical technology, announced it will participate in the Barclays Global Healthcare Conference 2019 on Tuesday, March 12, 2019, in Miami, Florida.
Medtronic plc, the global leader in medical technology, announced it will participate in the 39th Annual Cowen and Company Healthcare Conference on Monday, March 11, 2019, in Boston, Massachusetts.
Medtronic Announces Approval and Launch of Japan's First DBM Bone Grafting Product for Spine and Orthopedic Procedures
Grafton(TM) DBM Product Will Provide More Options for Spine and Orthopedic Surgeons in Japan
MEDTRONIC ANNOUNCES FDA CLEARANCE AND U.S. LAUNCH OF THE ACCURIAN RADIO FREQUENCY SYSTEM FOR NERVE TISSUE ABLATION
Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the Accurian™ RF ablation platform, which conducts radio frequency (RF) ablation of nerve tissues
Medtronic Resolute(TM) Drug-Eluting Stent (DES) Platform Receives Expanded Indication for Treatment of Chronic Total Occlusion (CTO)
FDA Approval Allows Interventional Cardiologists Access to Resolute DES Technology to Treat De Novo CTO
Medtronic Wraps Up Scientific Data Presentations at the Advanced Technologies and Treatments for Diabetes International Conference
Medtronic plc, the global leader in medical technology, announced a successful conclusion to the 12th International Conference on Advanced Technologies & Treatments for Diabetes, which took place in Berlin from February 20 - 23, 2019.